Celemics, Inc. has developed a NGS-based antibody sequencing platform with the aim to overcome key issues of sequencing error, short-read length and high-cost gene synthesis for further characterization. Celemics’ newly developed platform, TrueRepertoireTM will allow you to sequence scFv or Fab library, analyze the entire variable region and process >10,000 clones for a single experiment.